HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N(G)-monomethylarginine acetate

nitric oxide synthase inhibitor

Also Known As:

L-N(G)-mono-methylarginine acetate; tilarginine acetate

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675

Experts

1.	Alexander, John H: 2 articles (02/2014 - 04/2007)
2.	Hochman, Judith S: 2 articles (02/2014 - 04/2007)
3.	Reynolds, Harmony R: 2 articles (02/2014 - 04/2007)
4.	Baran, David A: 1 article (02/2014)
5.	Dauerman, Harold L: 1 article (02/2014)
6.	Džavík, Vladimír: 1 article (02/2014)
7.	Geppert, Alexander: 1 article (02/2014)
8.	Lopes, Renato D: 1 article (02/2014)
9.	Ohman, E Magnus: 1 article (02/2014)
10.	Parrillo, Joseph E: 1 article (02/2014)

Related Diseases

1.	Cardiogenic Shock 04/18/2007 - "Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial." 04/18/2007 - "International, multicenter, randomized, double-blind, placebo-controlled trial (Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock [TRIUMPH]) with planned enrollment of 658 patients at 130 centers. " 02/01/2014 - "In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received β or renin-angiotensin-aldosterone system blockers (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or aldosterone antagonists) within 24 hours of randomization with those who did not. "
2.	Myocardial Infarction 04/18/2007 - "Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial." 02/01/2014 - "In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received β or renin-angiotensin-aldosterone system blockers (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or aldosterone antagonists) within 24 hours of randomization with those who did not. "

Related Drugs and Biologics

1.	Angiotensin Receptor Antagonists
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.	Mineralocorticoid Receptor Antagonists
4.	AT 130